Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Romifidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C known ✓ | P18825 | 12/20 | 0.57 |
| ▸ | ADRA2A known ✓ | P08913 | 11/20 | 0.57 |
| ▸ | ADRA2B known ✓ | P18089 | 11/20 | 0.57 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.57 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.57 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 0.57 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.57 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.57 |
| ▸ | HTR1D known ✓ | P28221 | 3/20 | 0.55 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.55 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.55 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.55 |
| ▸ | CFB known ✓ | P00751 | 3/20 | 0.51 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.51 |
| ▸ | HTR1B known ✓ | P28222 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | BLM | P54132 | 3/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Romifidine SCHEMBL29761110 | 0.98 | ADRA2C (0.56) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL246009 | 0.98 | ADRA2C (0.56) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616284 | 0.97 | ADRA2C (0.55) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616210 | 0.91 | ADRA2C (0.49) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616255 | 0.91 | ADRA2C (0.49) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616229 | 0.90 | ADRA2C (0.48) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Hydrochloric Acid SCHEMBL11857722 | 0.89 | ADRA2C (0.66) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616310 | 0.88 | HTR1D (0.50) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| SCHEMBL11182818 | 0.88 | ADRA2C (0.65) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| SCHEMBL9920134 | 0.88 | ADRA2C (0.65) | ADRA2CADRA2AADRA2BADRA1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020222192-A1 | METHODS OF TREATING PRURITUS | CLEXIO BIOSCIENCES LTD. (IL) | 2020-11-05 | — | — | WO | claimed |
| US-12501899-B2 | Mite infestation treatment | VETO-PHARMA (FR) | 2025-12-23 | — | — | US | disclosed |
| US-20230023961-A1 | MITE INFESTATION TREATMENT | VETO-PHARMA (FR) | 2023-01-26 | — | — | US | disclosed |
| EP-4072293-A1 | MITE INFESTATION TREATMENT | Veto-Pharma (FR) | 2022-10-19 | — | — | EP | disclosed |
| US-20220211672-A1 | METHODS OF TREATING PRURITUS | CLEXIO BIOSCIENCES LTD. (IL) | 2022-07-07 | — | — | US | disclosed |
| WO-2021116631-A1 | MITE INFESTATION TREATMENT | VETO-PHARMA (FR) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116541-A1 | MITE INFESTATION TREATMENT | VETO-PHARMA (FR) | 2021-06-17 | — | — | WO | disclosed |
| EP-2686012-B1 | EQUINE RHINITIS VACCINE | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2020222192-A1 | METHODS OF TREATING PRURITUS | CLEXIO BIOSCIENCES LTD. (IL) | 2020-11-05 | — | — | WO | disclosed |
| EP-3694489-A2 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY | Illustris Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-2772266-A1 | Equine Rhinitis vaccine | Boehringer Ingelheim Vetmedica, Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8821889-B2 | West Nile Virus vaccine | BOEHRINGER INGELHEIM VETMEDICA, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| CN-102348466-B | West nile virus vaccine | BOEHRINGER INGELHEIM VETMED | 2014-05-07 | — | — | CN | disclosed |
| EP-2686012-A2 | EQUINE RHINITIS VACCINE | Boehringer Ingelheim Vetmedica, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20120237543-A1 | EQUINE RHINITIS VACCINE | BOEHRINGER INGELHEIM VETMEDICA, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012125525-A2 | EQUINE RHINITIS VACCINE | BOEHRINGER INGELHEIM VETMEDICA, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| CN-102348466-A | West nile virus vaccine | BOEHRINGER INGELHEIM VETMED | 2012-02-08 | — | — | CN | disclosed |
| US-20110159033-A1 | WEST NILE VIRUS VACCINE | BOEHRINGER INGELHEIM VETMEDICA, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| EP-2334327-A1 | WEST NILE VIRUS VACCINE | Boehringer Ingelheim Vetmedica, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010025469-A1 | WEST NILE VIRUS VACCINE | BOEHRINGER INGELHEIM VETMEDICA, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237543-A1 | EQUINE RHINITIS VACCINE | EXOSC9, EXOSC4, EXOSC5 | ADRA2C 1301/4885ADRA2A 933/4885ADRA2B 361/4885 |
| US-20230023961-A1 | MITE INFESTATION TREATMENT | RHOA, NPEPPS, TUBA3E | ADRA2C 2479/4885ADRA2A 3402/4885ADRA2B 3269/4885 |
| US-12501899-B2 | Mite infestation treatment | RHOA, NPEPPS, TUBA3E | ADRA2C 2479/4885ADRA2A 3402/4885ADRA2B 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.